| Suche Service: |
|
Popular Städte Zürich Basel Winterthur Bern Luzern St. Gallen Genève Lugano Thun Frauenfeld Neuchâtel Schaffhausen Chur Zug Fribourg La Chaux-De-Fonds Dübendorf Olten Vevey Bellinzona |
|
Anzeige: |
| Anzeige: |
1228 Plan-Les-Ouates Chemin Des Aulx 12
Addex Pharmaceuticals Sa Karte
Addex Pharmaceuticals Sa
Telefon: (022) 884 15 55
Webseite (addexpharma.com)
Anzeige:
holdinggesellschaften, investmentgesellschaften, dienstleistungen
Dienstleistung Kategorien
holdinggesellschaften investmentgesellschaften dienstleistungenBezogene Services
Anzeige:expanding the realm of possible...
Addex Therapeutics is pioneering ;discovery and development of an emerging class of oral ;small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended ;target ;and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including G-Protein Coupled Receptors (GPCRs), receptor tyrosine kinases (RTKs) and cytokine receptors, such as the TNF receptor superfamily. ;Many such targets ;have been widely ;recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery.
The Company’s two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc., to treat schizophrenia. Addex also is advancing several preclinical programs including: GABA-BR PAM for ;overactive bladder and other disorders; mGluR4 PAM for Parkinson's, MS and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression. In addition, Addex has discovery programs to identify allosteric modulators including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer’s, Parkinson’s and Huntington’s diseases) TNFR1 NAM for inflammation (e.g. rheumatoid arthritis) and other diseases.
;
Program on track for IND ;filing before end of 2012 GABA-BR PAM compounds have potential in several major Indications
Geneva,...
Addex expects data from dipraglurant trial
23 Feb 2012 MedNous - Addex Pharmaceuticals Ltd expects to report top-line data at the end of March for its lead allosteric modulator that is being
developed to treat patients with Parkinson’s disease who experience dyskinesia...
Geneva, ;Switzerland, 21 March 2012 - ;Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today...
Financial Highlights ;
Cash and cash equivalents of CHF36.1 million at 31 December 2011 Cash can fund operations through to 3Q 2013 Restructuring and pipeline...
New Addex CEO wants to prioritize pipeline quickly
Addex Pharmaceuticals’ new CEO Dr Bharatt Chowrira says he feels a sense of urgency to get on with decision-making at the allosteric modulation-focused Swiss company.
Refining GPCR Discovery Approaches
Emerging Platforms Afford Timelines More Comparable to Those for Soluble Targets.
Structures May Not Solve Everything
This week’s C&EN cover story is about how X-ray crystal structures of G-protein coupled receptors (GPCRs) help the hunt for new drugs. GPCRs are already a major target for drugs (if not the most popular drug target), but until...
Addex's return to basics strategy sees 2 drugs entering Phase II studies this month
BERLIN, March 14 (APM) - Swiss biotech Addex seems to have turned the corner after the failure of its lead compound during Phase II testing at the end of 2009, with two compounds entering Phase II studies within the next few...
BioCentury This Week: Katie Hood discusses funding Parkinson's disease research
BioCentury Washington Editor Steve Usdin recaps that disease groups provide urgency, a unique perspective on risk and a reminder that patients still demand drugs in an era of healthcare cost-cutting.
Addex Pharma wins EuropaBio's Most Innovative Biotech SME Award 2010
Brussels - Video coverage from the event.
Addex wins EuropaBio’s European Biotech SME Award
Geneva/Brussels – Swiss biotech company Addex Pharmaceuticals S.A. is the first winner of EuropaBio’s new ”Most Innovative European Biotech SME Award”.
Therapeutic focus - Parkinson's dyskinesia treatments making progress
The cornerstone of Parkinson’s disease treatment, levodopa, is an effective yet tainted drug - eventually causing side effects as debilitating as the disease it treats.
Glutamate Modulation as Parkinson’s Therapy
Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes.
Dissipating a slow torture
While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea...
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Less than a year after halting its lead program due to liver toxicity signals, Addex Pharmaceuticals has lined up two new sources of financing in two weeks and plans to go forward with a pair of Phase II trials for its new lead...
Actor’s charity to back Swiss drug trial
A Switzerland based pharmaceutical company has turned to a US charity to support its drug development programme as it diversifies fundraising away from a shrinking pool of private investors during the economic slowdown.
The Pink Sheet Daily: Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side
The Michael J. Fox Foundation awarded Addex Pharmaceuticals $900,000 to help pay for a Phase II study testing its mGLuR5 modulator ADX48621 for treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), the company...
Addex makes plans to move mGluR2 antagonist into clinical trials for Alzheimer's disease
Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year.
Rhythm and Blues: The Case for Allosteric Modulators
Switzerland’s Addex Pharmaceuticals rides optimism after drug setback.
Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators
Addex Pharmaceuticals pulled out all the stops to inspire confidence in its allosteric modulator platform during its R&D day May 11, with presentations designed to demonstrate the breadth of its discovery and development...
Allosteric drugs promise precise control over diseases mediated by G-protein-coupled receptors
“There’s a little yellow pill,” the Rolling Stones once crooned, to get mom through her busy day. Whether or not the song was about Valium, the sedative became “mother’s little helper” for a generation.
Developing a new class of APIs - allosteric modulators
Allosteric modulators bind receptors at sites that are distinct from the binding sites used by classical drugs and may therefore offer more sophisticated ways to normalise biological signaling compared to small-molecule drugs....
Dimmer-switch Drugs
A growing number of companies are exploring molecules that modulate targets, rather than just switching them on or off.
Adventures in glutamate: the difficult and expensive path of novelty in drug discovery
Efforts to target inscrutable glutamate GPCRs have helped change the way industry discovers small molecule therapeutics, opening up swathes of promising drug targets. But the decades-long effort also reveals problems with today's...
Addex Hitting New Targets with Allosteric Modulators
Addex Pharmaceuticals has unveiled the prospect of
oral drugs that directly target the tumor necrosis facto
(TNF) inflammatory cascade.
Brainstorm at Roche Leads to New Valium-Like Drugs
Vincent Mutel saw so much potential in a new way of tweaking the brain's circuitry that he left a job he'd had for 15 years to bet his future on a start-up.
How Addex Pharmaceuticals secured two multi-million dollar deals with Merck
MedNous, a medical business journal, featured the deals with Merck & Co., Inc.
Merck and Addex Reach Deal On Developing Schizophrenia Drug
Addex Pharmaceuticals and Merck & Co. reached a deal to develop a drug candidate for schizophrenia, under which the blue-chip drug giant will pay the Swiss firm up to $702 million in cash plus royalties, the companies announced...
Addex Therapeutics is pioneering ;discovery and development of an emerging class of oral ;small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended ;target ;and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including G-Protein Coupled Receptors (GPCRs), receptor tyrosine kinases (RTKs) and cytokine receptors, such as the TNF receptor superfamily. ;Many such targets ;have been widely ;recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery.
The Company’s two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc., to treat schizophrenia. Addex also is advancing several preclinical programs including: GABA-BR PAM for ;overactive bladder and other disorders; mGluR4 PAM for Parkinson's, MS and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression. In addition, Addex has discovery programs to identify allosteric modulators including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer’s, Parkinson’s and Huntington’s diseases) TNFR1 NAM for inflammation (e.g. rheumatoid arthritis) and other diseases.
;
Program on track for IND ;filing before end of 2012 GABA-BR PAM compounds have potential in several major Indications
Geneva,...
Addex expects data from dipraglurant trial
23 Feb 2012 MedNous - Addex Pharmaceuticals Ltd expects to report top-line data at the end of March for its lead allosteric modulator that is being
developed to treat patients with Parkinson’s disease who experience dyskinesia...
Geneva, ;Switzerland, 21 March 2012 - ;Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today...
Financial Highlights ;
Cash and cash equivalents of CHF36.1 million at 31 December 2011 Cash can fund operations through to 3Q 2013 Restructuring and pipeline...
New Addex CEO wants to prioritize pipeline quickly
Addex Pharmaceuticals’ new CEO Dr Bharatt Chowrira says he feels a sense of urgency to get on with decision-making at the allosteric modulation-focused Swiss company.
Refining GPCR Discovery Approaches
Emerging Platforms Afford Timelines More Comparable to Those for Soluble Targets.
Structures May Not Solve Everything
This week’s C&EN cover story is about how X-ray crystal structures of G-protein coupled receptors (GPCRs) help the hunt for new drugs. GPCRs are already a major target for drugs (if not the most popular drug target), but until...
Addex's return to basics strategy sees 2 drugs entering Phase II studies this month
BERLIN, March 14 (APM) - Swiss biotech Addex seems to have turned the corner after the failure of its lead compound during Phase II testing at the end of 2009, with two compounds entering Phase II studies within the next few...
BioCentury This Week: Katie Hood discusses funding Parkinson's disease research
BioCentury Washington Editor Steve Usdin recaps that disease groups provide urgency, a unique perspective on risk and a reminder that patients still demand drugs in an era of healthcare cost-cutting.
Addex Pharma wins EuropaBio's Most Innovative Biotech SME Award 2010
Brussels - Video coverage from the event.
Addex wins EuropaBio’s European Biotech SME Award
Geneva/Brussels – Swiss biotech company Addex Pharmaceuticals S.A. is the first winner of EuropaBio’s new ”Most Innovative European Biotech SME Award”.
Therapeutic focus - Parkinson's dyskinesia treatments making progress
The cornerstone of Parkinson’s disease treatment, levodopa, is an effective yet tainted drug - eventually causing side effects as debilitating as the disease it treats.
Glutamate Modulation as Parkinson’s Therapy
Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes.
Dissipating a slow torture
While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea...
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Less than a year after halting its lead program due to liver toxicity signals, Addex Pharmaceuticals has lined up two new sources of financing in two weeks and plans to go forward with a pair of Phase II trials for its new lead...
Actor’s charity to back Swiss drug trial
A Switzerland based pharmaceutical company has turned to a US charity to support its drug development programme as it diversifies fundraising away from a shrinking pool of private investors during the economic slowdown.
The Pink Sheet Daily: Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side
The Michael J. Fox Foundation awarded Addex Pharmaceuticals $900,000 to help pay for a Phase II study testing its mGLuR5 modulator ADX48621 for treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), the company...
Addex makes plans to move mGluR2 antagonist into clinical trials for Alzheimer's disease
Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year.
Rhythm and Blues: The Case for Allosteric Modulators
Switzerland’s Addex Pharmaceuticals rides optimism after drug setback.
Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators
Addex Pharmaceuticals pulled out all the stops to inspire confidence in its allosteric modulator platform during its R&D day May 11, with presentations designed to demonstrate the breadth of its discovery and development...
Allosteric drugs promise precise control over diseases mediated by G-protein-coupled receptors
“There’s a little yellow pill,” the Rolling Stones once crooned, to get mom through her busy day. Whether or not the song was about Valium, the sedative became “mother’s little helper” for a generation.
Developing a new class of APIs - allosteric modulators
Allosteric modulators bind receptors at sites that are distinct from the binding sites used by classical drugs and may therefore offer more sophisticated ways to normalise biological signaling compared to small-molecule drugs....
Dimmer-switch Drugs
A growing number of companies are exploring molecules that modulate targets, rather than just switching them on or off.
Adventures in glutamate: the difficult and expensive path of novelty in drug discovery
Efforts to target inscrutable glutamate GPCRs have helped change the way industry discovers small molecule therapeutics, opening up swathes of promising drug targets. But the decades-long effort also reveals problems with today's...
Addex Hitting New Targets with Allosteric Modulators
Addex Pharmaceuticals has unveiled the prospect of
oral drugs that directly target the tumor necrosis facto
(TNF) inflammatory cascade.
Brainstorm at Roche Leads to New Valium-Like Drugs
Vincent Mutel saw so much potential in a new way of tweaking the brain's circuitry that he left a job he'd had for 15 years to bet his future on a start-up.
How Addex Pharmaceuticals secured two multi-million dollar deals with Merck
MedNous, a medical business journal, featured the deals with Merck & Co., Inc.
Merck and Addex Reach Deal On Developing Schizophrenia Drug
Addex Pharmaceuticals and Merck & Co. reached a deal to develop a drug candidate for schizophrenia, under which the blue-chip drug giant will pay the Swiss firm up to $702 million in cash plus royalties, the companies announced...
Anzeige: